Top 5 Companies in the Global Diabetic Gastroparesis Treatment Market in 2025

The global diabetic gastroparesis treatment market was valued at USD 3.64 billion in 2024, fueled by advancements in healthcare and gastric disorder management. The market is expected to grow at a CAGR of 4.10% from 2025 to 2034, reaching approximately USD 5.44 billion by 2034.

Gastroparesis, also known as delayed gastric emptying, can be defined as a disease of the stomach muscles or the nerves controlling these muscles that causes the stomach muscles to stop functioning. It affects the spontaneous movement of the stomach muscles. Stomach emptying is caused by a lack of movement in the stomach muscles. Gastroparesis occurs due to damage to the vagus nerve either because of injury or illness. It commonly occurs among people and known as idiopathic gastroparesis, indicating that the actual cause of the disease is unclear. Diabetes is another cause of gastroparesis, as high blood sugar levels lead to slow damage of the vagus nerve, causing gastroparesis. The common symptoms of the disease include nausea, feeling of fullness, gastroesophageal reflux, abdominal bloating, lack of appetite, and pain in the stomach area.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

The global gastroparesis treatment market is anticipated to record moderate growth during the forecast period. Expansion of the market can be attributed to an increase in the prevalence of diabetes mellitus among people, rise in the number of surgeries being performed which could lead to post-operative gastroparesis, the introduction of novel drugs, and focus of market players on research and development to launch specific medications for the treatment of gastroparesis. Additionally, untapped opportunities in emerging markets, such as India and China, are likely to fuel the market's growth. However, usage of non-prescription drugs, side effects of available gastroparesis drugs, and a stringent regulatory environment for the approval of new drugs are expected to restrain the market during the forecast period.

Top Global Diabetic Gastroparesis Treatment Companies:

1. Evoke Pharma

Evoke Pharma, Inc. is a speciality pharmaceutical company focused primarily on developing drugs to treat gastrointestinal or G.I. disorders and diseases. The company has developed Gimoti, a metoclopramide nasal spray to relieve symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. Before the development and approval of Gimoti, Metoclopramide was the only product approved in the United States to treat gastroparesis and available only in oral and intravenous forms. Gimoti is a novel formulation of this drug, designed to provide systemic delivery of metoclopramide through intranasal administration.

2. Allergan Plc

Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in medical aesthetics, eye care, central nervous system, and gastroenterology. In June 2019, United SStates pharmaceutical company AbbVie announced it had reached an agreement to acquire Allergan for USD 63 billion. The merged company would be domiciled in the United States for tax purposes.

3. Salix Pharmaceuticals, Inc.

Salix Pharmaceuticals, Inc. is an American speciality pharmaceutical company. It is the largest gastroenterology-focused pharmaceutical company in the world. Salix develops prescription drugs and medical devices that prevent and treat various gastrointestinal disorders.

4. Theravance Biopharma

Theravance Biopharma, Inc. ("Theravance Biopharma") is a diversified biopharmaceutical company primarily focused on discovering, developing, and commercialising organ-selective medicines. The purpose is to create transformational drugs to improve the lives of patients suffering from serious illnesses. Its research is focused on the areas of inflammation and immunology.

5. Medtronic plc

Medtronic plc is an American Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota, in the United States. In 2015, Medtronic acquired Irish–tax registered Covidien (a United States tax inversion to Ireland from 2007), in the most significant United States corporate tax inversion in history, which enabled Medtronic to move its legal registration from the United States to Ireland. Medtronic operates in 140 countries and employs over 1,04,950 people.